A FDA Perspective on Quality by Design

Published on: 

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-12-05-2007, Volume 3, Issue 12

Chi-wan Chen, deputy director of the Office of New Drug Quality Assessment (ONDQA) at the US Food and Drug Administration's Center for Drug Evaluation and Research, shares insight from FDA's pilot program that was designed to allow pharmaceutical companies to submit CMC information demonstrating application of quality by design.

The adoption of quality by design (QbD) in the pharmaceutical industry is an evolving process. To faciliate the implementation of QbD, the launched a pilot program in 2005 to allow participating firms an opportunity to submit chemistry, manufacturing, and controls (CMC) information demonstrating application of QbD. Chi-wan Chen, deputy director of the Office of New Drug Quality Assessment (ONDQA) at FDA's Center for Drug Evaluation and Research, recently outlined some key lessons learned from the CMC pilot. Chen described the progress of the initiative at Regulatory Watch 2007, a conference held in September by the (Robbinsville, NJ) in conjunction with

FDA launched the CMC pilot in July 2005 to evaluate the utility of comprehensive Quality Overall Summary as part of a new drug application (NDA) and to implement new concepts such as QbD, design space, and real-time release contained in the International Conference on Harmonization's guidances, and and the FDA process analytical technology (PAT) guidance.

Nine original new drug applications (NDAs) and two supplemental NDAs were accepted into the pilot program. As of Sept. 19, 2007, seven of these NDAs had been submitted, of which six were approved and one was under review. FDA expects to receive the remaining four NDAs in the next six months, with the goal of concluding the pilot by the end of 2008, says Chen.

The pilot has allowed FDA and industry to work together to explore various ways to implement ICH Q8, ICH Q9, and FDA PAT guidances.

Chen began by outlining FDA's view of QbD. "QbD is a systematic approach to product and process design and development," she says. QbD involves the following key elements:

  • Target the product profile

  • Determine critical quality attributes (CQAs)

  • Link raw material attributes and process parameters to CQAs and perform risk assessment

  • Develop a design space

  • Design and implement a control strategy

  • Manage product life cycle, including continual improvement.

Chen then shared some observations made from the CMC pilot as they relate to CQAs, risk assessment, design space, and control strategy. The lessons learned from the CMC pilot are being considered in the revision of ICH Q8.

The revision of ICH Q8, or ICH Q8 (R1), is an annex to ICH Q8. It provides further clarification of key concepts outlined in the core guideline and describes the principles of QbD. Q8(R1) was signed off by the ICH Expert Working Group as a draft (or Step-2) guidance on Nov. 1, 2007, and will soon be published for public comment in each ICH region (Europe, Japan, and the United States).

Critical quality attributes

Chen described some observations on CQAs. These were:

  • Definition of "critical" varied

  • Most of the applications related CQAs to those attributes that have a direct impact on product quality, safety, and efficacy

  • Most applications included CQAs for the drug product, but only some applications included CQAs for the drug substance

  • Some applications considered the drug substance's property affecting downstream manufacturing as a CQA

  • Most applications related critical process parameters to CQAs

  • Most applications considered a process parameter noncritical if well controlled or well within the design space.

"A question arises on whether a process parameter may be considered noncritical if it is well controlled or well within the design space," says Chen. "This issue is being considered more fully in the revised ICH Q8," she says.

Risk assessments

Chen noted that several applications in the CMC pilot included risk assessments, especially for the drug product by linking input and process variables to CQAs. Tools used in the risk assessment included the Ishikawa or fishbone diagram, failure mode effect analysis (FMEA), and Pareto analysis. An Ishikawa or fishbone diagram is used to identify all potential variables, such as raw materials, compression parameters, and environmental factors, which can have an impact on a particular CQA, such as tablet hardness. A FMEA can then be used to rank the variables based on risk (i.e., a combination of probability, severity, and detectability) and to select the process parameters with higher risks for further studies to gain greater understanding of their effects on CQAs. The risk assessment is amassed by a multidisciplinary team based on prior knowledge and experiments.

"It is important to provide a systematic risk analysis of how raw materials, process steps, and process parameters affect product quality," says Chen. "One of the points to consider in risk assessment," she says "is to provide an explanation when citing prior experience as the basis for assigning risk. The risk assessment that leads to the development of a comprehensive control strategy to reduce risk to product quality should be described, and the risk reduction and control should be discussed for changes that occur inside or outside the design space, " she says.

"Risk assessment can provide increased assurance to quality," emphasized Chen, because "process variability is identified and its linkage to product CQAs is understood; process and product controls reduce the impact of variability; and quality product will continue to be made when movement within the design space occurs in the future."

A risk assessment also is important for effective communication between FDA and industry and for intracompany communication (such as between research/development and manufacturing and among multiple manufacturing sites), says Chen. "And within FDA, risk assessment allows for a dialogue between pre-and post-marketing review functions and among review, compliance, and field inspection staffs."

Design space

Chen also shared some observations from the CMC pilot for design space. "Most applications included a design space for the drug product, but only some included a design space for the drug substance," she says. Most of the applications included design spaces for process parameters, but only some included design spaces for formulation components (i.e., excipients and drug-substance) properties. Methods for determining design space included: one-variable-at-a-time experiments, statistically designed experiments, and modeling approaches. Methods for presenting design space included graphs (surface-response curves and contour plots), linear combination of parameter ranges, equations, and models.

In establishing and presenting a design space, Chen identified certain key points to consider:

  • Effect of formulation-component properties on process performance and product quality studied

  • Multivariate interactions examined

  • Supportive mathematical models used, as appropriate

  • Scale-up and equipment issues considered

  • Effect of operation or site change considered

  • Uncertainty addressed with risk management.

Control strategy

Control strategy also is a critical element of QbD, and Chen outlined some points for potential applications to consider when establishing a control strategy. "The control strategy should be comprehensive," she says, "and should include raw-material properties and intermediates, in-process controls, and specifications for the drug substance and drug product. It is also important that the strategy demonstrate control of excipient properties based on the understanding of their effects and not relying solely on compendial standards," she says.

Other points to consider are:

  • Better use of process knowledge and understanding in setting specifications

  • More meaningful sampling for drug-product testing

  • Experience needed in setting real-time release specifications.

Chen mentioned that both industry and FDA are "on a learning curve" as it relates to the acceptance criteria for real-time release. She pointed out, however, real-time release provides manufacturing flexibility and increased quality assurance and is a more modern approach to manufacturing and controls.

"More scientific information was shared with FDA in the pilot NDAs," says Chen, and "elements of QbD were applied and risk-based regulatory decisions were enabled." She concluded that the pilot benefited FDA and industry in implementing QbD, although challenges (e.g., cultural change, knowledge, and resources) remain for both.